Reata Pharmaceuticals Plans NDA Submission for Omaveloxolone in First Quarter of 2022 Following Completion of Pre-NDA Meeting with FDA

Read also

Myeloma

Myeloma treatment HDP-101 put on FDA fast track

Evotec Announces Progress

Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb

Tylenol (paracetamol)

Tylenol (paracetamol) fights autism claims, slams proposed FDA warning label as 'unsupported' by science

Cullinan Therapeutics showcases

Cullinan Therapeutics showcases preclinical data for autoimmune drug CLN-978